clonazepam has been researched along with Lennox Gastaut Syndrome in 1 studies
Clonazepam: An anticonvulsant used for several types of seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop. It is seldom effective in generalized tonic-clonic or partial seizures. The mechanism of action appears to involve the enhancement of GAMMA-AMINOBUTYRIC ACID receptor responses.
clonazepam : 1,3-Dihydro-2H-1,4-benzodiazepin-2-one in which the hydrogens at positions 5 and 7 are substituted by 2-chlorophenyl and nitro groups, respectively. It is used in the treatment of all types of epilepsy and seizures, as well as myoclonus and associated abnormal movements, and panic disorders. However, its use can be limited by the development of tolerance and by sedation.
Lennox Gastaut Syndrome: A childhood-onset epilepsy syndrome.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Following its clinical development, in September 2019 the European Medicines Agency approved its indication for the adjunctive therapy of epileptic seizures associated with Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS), combined with clobazam (CLB), in patients of 2 years of age and older." | 9.12 | Cannabidiol for the treatment of Lennox-Gastaut syndrome and Dravet syndrome: experts' recommendations for its use in clinical practice in Spain. ( García-Peñas, JJ; Gil Nagel-Rein, A; Sánchez-Carpintero, R; Villanueva-Haba, V, 2021) |
| " Following its clinical development, in September 2019 the European Medicines Agency approved its indication for the adjunctive therapy of epileptic seizures associated with Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS), combined with clobazam (CLB), in patients of 2 years of age and older." | 5.12 | Cannabidiol for the treatment of Lennox-Gastaut syndrome and Dravet syndrome: experts' recommendations for its use in clinical practice in Spain. ( García-Peñas, JJ; Gil Nagel-Rein, A; Sánchez-Carpintero, R; Villanueva-Haba, V, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| García-Peñas, JJ | 1 |
| Gil Nagel-Rein, A | 1 |
| Sánchez-Carpintero, R | 1 |
| Villanueva-Haba, V | 1 |
1 review available for clonazepam and Lennox Gastaut Syndrome
| Article | Year |
|---|---|
Cannabidiol for the treatment of Lennox-Gastaut syndrome and Dravet syndrome: experts' recommendations for its use in clinical practice in Spain.
Topics: Anticonvulsants; Cannabidiol; Clobazam; Clonazepam; Diazepam; Dioxolanes; Drug Administration Schedu | 2021 |